dpp-4

P32 98 hemifumarate is a dipeptidyl peptidase IV (DPP4) inhibitor with hypoglycemic properties that improves insulin sensitivity and β-cell responsiveness in the Zucker diabetic rat model, and may be useful in studies of type 2 diabetes and colitis.

TS-021 is a selective dipeptidyl peptidase 4 (DPP-4) inhibitor with antidiabetic activity for the study of type 2 diabetes.

Linagliptin (BI 1356) is a potent, orally bioavailable dihydropurinedione-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity.

Denagliptin is a small molecule dipeptidyl peptidase IV (DPP-4) inhibitor for the treatment of endocrine Ü metabolic diseases and can be used in the study of type 2 diabetes.

Retagliptin Phosphate (SP 2086) is pharmaceutical composition of DPP-4 inhibitor, for treating type-2 diabetes.

γ-Glu-Tyr (gamma-Glutamyltyrosine) is a kokumi peptide with competitive inhibition of dipeptidyl peptidase-IV (DPP-IV) and is used in the study of diabetes mellitus.

DPP-4-IN-11 (compound 10) is an orally active DPP-4 inhibitor (IC50=2.75 μM) with anti-type 2 diabetes activity. This compound exerts its hypoglycemic effects by inhibiting the activity of α-glucosidase (IC50=3.02 μM) and α-amylase (IC50=3.3 μM).

DPP-4 GPR119 modulator 2 is an inhibitor of dipeptidyl peptidase IV (DPP-IV) (IC50: 0.22 μM) and an agonist of GPR119 (EC50: 0.95 μM).

Compound 5a, also known as DPP-4 inhibitor 3, is a powerful dipeptidyl peptidase IV (DPP-IV) inhibitor, demonstrating an IC50 value of 0.75 nM. It exhibits outstanding antioxidant and insulinotropic activity [1].

DPP-4-IN-15 (Compound 22) is a non-competitive inhibitor of dipeptidyl peptidase-4 (DPP-4) with an IC50 value of 8.24 μM.

DPP-4 GPR119 modulator 1 (Compound 22) is an orally active compound that acts as both a dipeptidyl peptidase IV (DPP-IV) inhibitor and GPR119 agonist, demonstrating a glucose-lowering effect in blood and moderate inhibition of the hERG channel with an IC50 value of 4.9 µM. This compound is applicable in diabetes research [1].

DPP-4-IN-12 (compound 46) is an effective DPP-4 inhibitor with an IC50 of 2 nM, utilized in the study of type 2 diabetes.

DPP-4-IN-9 (compound 6l) is a potent dipeptidyl peptidase DPP-4 inhibitor, exhibiting an IC50 of 8.22 nM. Additionally, this compound demonstrates antihyperglycemic activity [1].

DPP-4-IN-8 (compound 27) is a potent and selective inhibitor of dipeptidyl peptidase 4 (DPP4), with an inhibition constant (Ki) of 0.96 μM. It inhibits the dipeptidase activity of DPP4 in both Caco-2 and HepG-2 cells and dose-dependently reduces the expression of chemokines such as tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β) [1].

DPP-4-IN-2 (compound b2) is a structural analog of Alogliptin and a potent dipeptidyl peptidase 4 (DPP-4) inhibitor with an IC50 value of 79 nM [1], suitable for diabetes research.

DPP-4-IN-14 (compound 30) is an inhibitor of DPP-4, with an IC50 value of 12.82 nM.

DPP-4-PIOL is an antagonist of GABAA. In dentate gyrus granule cells, it acts by selectively antagonizing tonic over phasic GABAergic currents.

DPP-4-IN-1 (compound d1) is a highly potent inhibitor of DPP-4 (dipeptidyl peptidase 4) with an IC50 of 49 nM, making it suitable for diabetes research [1]. Structurally similar to Alogliptin, it can be effectively utilized for studying diabetes-related mechanisms.

DPP-4-IN-13 (compound 9i) is a competitive inhibitor of DPP4, exhibiting an IC50 of 9.25 μM, making it suitable for research in type 2 diabetes.

Imigliptin (KBP 3853) is a novel dipeptidyl peptidase-4 inhibitor for the study of type 2 diabetes.

Trelagliptin (SYR-472) is a highly specific, long-acting DPP-4 inhibitor.

Saxagliptin hydrate (Onglyza hydrate) is a selective and reversible DPP4 inhibitor (IC50: 26 nM; Ki: 1.3 nM).

Anagliptin (SK-0403) is a potent inhibitor of DPP-4 (IC50 of 3.8 nM) used in the treatment of type 2 diabetes mellitus.